Descrizione del progetto DEENESFRITPL Rivoluzionare il processo di produzione alternativa di carne La crescente domanda di carne in combinazione con il tentativo di ridurre le emissioni totali di CO2 provenienti dagli allevamenti di bestiame ha portato al perseguimento di soluzioni biotecniche per la produzione della carne. Una delle principali pratiche introdotte per affrontare questa sfida è la produzione di carne ottenuta mediante coltura cellulare, un risultato raggiunto attraverso la crescita di cellule di carne a partire da un piccolo campione di cellule staminali raccolte dall’animale interessato. Il progetto CCMeat, finanziato dall’UE, introdurrà una serie di fattori di crescita innovativi, economici e privi di endotossine appositamente concepiti per l’industria della carne prodotta mediante coltura cellulare. Grazie alla sua tecnologia innovativa, CCMeat intende aiutare i produttori attivi in questa industria a immettere i propri prodotti di carne alternativa sul mercato e contribuire a ridurre le conseguenze negative della produzione di carne convenzionale. Mostra l’obiettivo del progetto Nascondi l’obiettivo del progetto Obiettivo ORF Genetics is a female-lead plant biotechnology company biofarming protein in barley for use in medical research, stem cell technology and skincare. Since 2001, we have produced over 50 proteins, specializing in human growth factors (GFs) which regulate the growth and development of cells. Our main focus has been on GFs for skincare use and now with our team of over 80 qualified scientists, researchers, marketers and more, we are aiming at a larger market, the cell-cultured meat (CCM) industry. The CCMeat project removes the biggest hurdle CCM producers are facing to bring their alternative meat products to market. With innovations in our technology we will produce affordable, endotoxin-free growth factors designed specifically for CCM: the MESOkine™ line (patent to be filed in June 2020). This will be done by scaling cultivation from our 2000m2 state-of-the-art geothermally powered greenhouse in Iceland to in-field cultivation sites. We will also introduce a protein processing technology (patent to be filed in July 2020) that will substantially decrease production costs and lead to greater GF yields. By 2030, our MESOkine™ line will drop GF prices from 3000€/kg of cultured meat to approximately 0.7€/kg meat at scales necessary to produce over 7 million tonnes of meat. We are already providing samples to CCM customers and expect to reach a 40% market share within 5 years with our strong first mover advantage. MESOkine™ sales are expected to rise exponentially and reach profitability of €19 million by 2026. As the demand for meat continues to grow, this innovation will have a profound impact on our planet, enabling CCM to avert many of the negative consequences of conventional meat production. This includes reducing greenhouse gases by more than 250 million tonnes of CO2-eq emissions, deforestation by producing 7-52 times as much meat with one hectare of land, and antibiotic resistance by sparing over 1000 tonnes of livestock antibiotic use. Campo scientifico natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsagricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandrymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Parole chiave Cell-cultured meat affordable synthetic meat growth factors biofarming barley Programma(i) H2020-EU.3. - PRIORITY 'Societal challenges Main Programme H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Argomento(i) H2020-EIC-SMEInst-2020-4 - H2020-EIC Accelerator pilot –SME Instrument - Green Deal Invito a presentare proposte H2020-EIC-SMEInst-2018-2020 Vedi altri progetti per questo bando Bando secondario H2020-EIC-SMEInst-2018-2020-4 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore ORF GENETICS HF Contribution nette de l'UE € 2 500 000,00 Indirizzo VIKURHVARF 7 IS-203 KOPAVOGUR Islanda Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Ísland Ísland Höfuðborgarsvæði Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 3 809 356,00
